(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 34.26% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Harrow's revenue in 2025 is $227,661,000.On average, 3 Wall Street analysts forecast HROW's revenue for 2025 to be $10,483,075,150, with the lowest HROW revenue forecast at $10,375,398,934, and the highest HROW revenue forecast at $10,691,027,154. On average, 3 Wall Street analysts forecast HROW's revenue for 2026 to be $15,159,405,098, with the lowest HROW revenue forecast at $14,097,813,816, and the highest HROW revenue forecast at $16,650,961,200.
In 2027, HROW is forecast to generate $20,554,686,548 in revenue, with the lowest revenue forecast at $18,793,754,896 and the highest revenue forecast at $22,315,618,200.